Our previous work has linked genomic instability with immune response in both ER+ and ER− participants, suggesting that immunogenic genomic instability is prognostically significant even in ER+ participants.12 However, immunogenic responses are difficult to detect in ER+ breast cancers as the TIL counts tend to be present at low or moderate levels. This evidence concerns the gene ESR1 and breast carcinoma.